Bessemer Group’s Immunovant IMVT Stock Holding History

Bessemer Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-50	Closed	-$1K	–	2590
2024 Q4	$1K	Hold	50	–	–	﹤0.01%	2355
2024 Q3	$1K	Buy	+50	New	+$1.48K	﹤0.01%	2436

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Bessemer Group's IMVT Position: Q1 2025 in Review

Bessemer Group sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 50 shares — an estimated $1K sold.

Bessemer Group first reported a position in IMVT in Q3 2024 and held it in 2 quarters. The position peaked at $1K in Q4 2024. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

Bessemer Group reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
Bessemer Group sold 50 Immunovant shares in Q1 2025, an estimated $1K.
Bessemer Group first reported a position in Immunovant in Q3 2024 and held it in 2 quarters.
Bessemer Group's Immunovant position peaked at $1K in Q4 2024.
193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Bessemer Group's 13F filing for Q1 2025, filed 23 Apr 2025.